Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) has shared an announcement.
Recordati has made its 2025 Annual Financial Report, including separate and consolidated financial statements, management reports with sustainability reporting, and accompanying auditors’ and statutory auditors’ reports, available to the public through its registered office, website and an authorized storage mechanism. The release also confirms public access to the 2025 Corporate Governance and Ownership Structure report and the Board of Directors’ report on approval of the 2025 financial statements and profit allocation, ahead of the ordinary and extraordinary shareholders’ meeting scheduled for 29 April 2026, enhancing transparency for investors and other stakeholders.
These disclosures provide shareholders with key financial, governance and sustainability information needed to evaluate the group’s performance and oversight framework before voting on the 2025 accounts. By publishing the documentation across multiple channels, Recordati reinforces its compliance with market disclosure requirements and supports informed participation in its upcoming shareholders’ meeting, which may influence future capital allocation and corporate policies.
The most recent analyst rating on (IT:REC) stock is a Buy with a EUR57.50 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica is an international pharmaceutical group listed on Borsa Italiana, offering therapies in both general and specialist medicine as well as treatments for rare diseases. The company operates in a fully integrated model from clinical development to production, marketing and licensing of active pharmaceutical ingredients and finished products, with a global presence across EMEA, the Americas and APAC.
Average Trading Volume: 369,229
Technical Sentiment Signal: Buy
Current Market Cap: €10.12B
For a thorough assessment of REC stock, go to TipRanks’ Stock Analysis page.